Henry E C, Gasiewicz T A
Environmental Health Sciences Center, University of Rochester Medical Center, New York 14642.
Arch Biochem Biophys. 1991 Jul;288(1):149-56. doi: 10.1016/0003-9861(91)90177-k.
The Ah receptor binds 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related aryl hydrocarbons and mediates their biochemical and toxic effects by modifying gene expression. In order to interact with DNA, the TCDD.receptor complex must undergo a poorly understood transformation to a form which is distinguishable by its increased affinity for DNA-Sepharose and for its specific enhancer element upstream from the cytochrome P450IA1 gene. We have found that this transformation process is inhibited in vitro by treatment of rat hepatic cytosol with activated charcoal prior to addition of [3H]TCDD. The transformed form of the receptor can be generated in the charcoal-inhibited cytosol by incubation with hepatic cytosol from either DBA/2J mice (in which [3H]TCDD-specific binding is undetectable under these conditions) or rat (in which Ah receptor was prebound with unlabeled ligand). Transformation is observed whether this addition occurs before or after [3H]TCDD is bound to the charcoal-treated receptor. Thus, transformation is (i) mediated by some additional cytosolic component(s) and (ii) separable from ligand binding. The untransformed [3H]TCDD.receptor complex, isolated by DNA-Sepharose chromatography, can also be transformed if DBA mouse hepatic cytosol is added. This partially purified untransformed receptor preparation and gel retardation analysis were used to further characterize the transforming activity in DBA cytosol. We observed that the "Ah receptor transforming factor" is heat-labile, trypsin-sensitive, removed or inactivated by charcoal, of greater than approximately 50 kDa, and elutes from Superose at a Rs of approximately 6 nm. In conjunction with our previous studies documenting the increased molecular weight of the transformed compared to the untransformed Ah receptor, and identifying the heteromeric structure of the transformed receptor, we postulate that the ligand-binding subunit (the untransformed receptor) must associate tightly with another cytosolic protein, which is also present in the receptor-defective DBA mouse, in order to transform to the transcriptionally active receptor.
芳烃受体可结合2,3,7,8-四氯二苯并-对-二恶英(TCDD)及相关芳烃,并通过改变基因表达介导其生化和毒性作用。为了与DNA相互作用,TCDD-受体复合物必须经历一种了解甚少的转变,成为一种对DNA-琼脂糖和细胞色素P450IA1基因上游特定增强子元件具有更高亲和力的形式。我们发现,在加入[3H]TCDD之前,用活性炭处理大鼠肝细胞溶胶可在体外抑制这种转变过程。通过与来自DBA/2J小鼠(在此条件下检测不到[3H]TCDD特异性结合)或大鼠(其中芳烃受体预先与未标记配体结合)的肝细胞溶胶孵育,可在活性炭抑制的细胞溶胶中产生受体的转变形式。无论这种添加是在[3H]TCDD与经活性炭处理的受体结合之前还是之后发生,均可观察到转变。因此,转变(i)由某些其他细胞溶质成分介导,(ii)与配体结合可分离。通过DNA-琼脂糖色谱法分离得到的未转变的[3H]TCDD-受体复合物,如果加入DBA小鼠肝细胞溶胶也可发生转变。这种部分纯化的未转变受体制剂和凝胶阻滞分析用于进一步表征DBA细胞溶胶中的转变活性。我们观察到“芳烃受体转变因子”对热不稳定、对胰蛋白酶敏感、可被活性炭去除或失活,分子量大于约50 kDa,在Superose上以约6 nm的保留体积洗脱。结合我们之前的研究,记录了与未转变的芳烃受体相比转变后的受体分子量增加,并鉴定了转变后受体的异源结构,我们推测配体结合亚基(未转变的受体)必须与另一种细胞溶质蛋白紧密结合,该蛋白也存在于受体缺陷的DBA小鼠中,以便转变为转录活性受体。